Asset
LONCASTUXIMAB TESIRINE
ADC Therapeutics SA Common Shares
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02669264 | phase1 | terminated | 2016-03-01 | 2018-07-03 | ADC Therapeutics S.A. | Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL) |
| NCT02669017 | phase1 | completed | 2016-03-01 | 2019-02-21 | ADC Therapeutics S.A. | Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) |
FDA applications (0)
This company has no applications containing this asset.